Skip to main content
SpringerLink
Log in

Preclinical Approaches for the Safety Assessment of Cytokines

  • Protocol
Cytokines in Human Health

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

  • 825 Accesses

Abstract

In response to the need to treat disorders such as Crohn’s disease, rheumatoid arthritis, allergies, and diabetes, the pharmaceutical industry has pursued the development of cytokines as therapeutic agents. Cytokines possess unique characteristics that are distinctly different than small molecule drugs. These hormone-like proteins possess complex structural features, demonstrate unique binding specificities and, in many cases, share overlapping physiological functions. These characteristics make development of cytokine therapeutics a challenge to drug-development scientists. Preclinical development of these molecules is complicated by the challenge of differentiating between toxicity and exaggerated immunopharmacology and understanding and analyzing the impact of antidrug antibody on the pharmacodynamics and pharmacokinetics of the parent compound. Regulatory agencies have recognized these issues and established guidance documents to address the nonclinical development of biological products. Several examples, including the nonclinical development of interleukin (IL)-, IL-5 antagonists, IL-6, IL-10, and IL-18 are reviewed in the context of these issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bloom B, Bennett B. Mechanism of a reaction in vitro associated with delayedtype hypersensitivity. Science 1966;153:80–82.

    Article  CAS  PubMed  Google Scholar 

  2. Cohen S, Bigazzi P, Yoshida T. Similarities of T-cell function in cell-mediated immunity and antibody production. Cell Immunol 1974; 12:150–159.

    Article  CAS  PubMed  Google Scholar 

  3. Mantovani A. Cytokines: A World Apart. In: Pharmacology of Cytokines. Oxford University Press New York, 2000, pp. 1–18.

    Google Scholar 

  4. Oppmann B, Lesley R, Blom B, et al. Novel pl9 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715–725.

    Article  CAS  PubMed  Google Scholar 

  5. Nicola NA. Cytokine pleiotropy and redundancy: a view from the receptor. Stem Cells 1994;12:(Suppl 1) 3–12.

    PubMed  Google Scholar 

  6. Vilcek J. The cytokines: an overview. In: Thompson A, ed. The Cytokine Handbook. 3rd ed. San Diego: Academic Press; 1998; 1–20.

    Google Scholar 

  7. Homey B. Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets 2004;3:169–174.

    Article  CAS  Google Scholar 

  8. Hendrick J, Zlotnick A. Chemokines and lymphocyte biology. Curr Opin Immunol 1996;8:343–347.

    Article  Google Scholar 

  9. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675–705.

    Article  CAS  PubMed  Google Scholar 

  10. Romagnani S. New therapeutic strategies in allergic diseases. Drugs Today 2003;39:849–865.

    Article  CAS  PubMed  Google Scholar 

  11. Schooltink H, Rose-John S. Cytokines as therapeutic drugs. J. Interferon and Cytokine Research 2002;22:505–516.

    Article  CAS  Google Scholar 

  12. International Conference on Harmonisation. Guidance S7A. Safety Pharmacology Studies for Human Pharmaceuticals; July 2001.

    Google Scholar 

  13. Weir A. Preclinical safety assessment of therapeutic proteins and monoclonal antibodies. In: Mathieu, M, ed. Biologies Development: A Regulatory Overview. 3rd ed. Waltham MA Parexel; 2004; 17–24.

    Google Scholar 

  14. Rosenblum I, Dayan, A. Carcinogenicity testing of IL-10: principles and practicalities. Human Exp Toxicol 2002;21:347–358.

    Article  CAS  Google Scholar 

  15. Ryan A, Terrell T. Biotechnology and its products. In: Haschek WM, Rousseaux CG, Wallig M, eds. Handbook of Toxicologic Pathology, 2nd ed., Vol 1. San Diego Academic Press; 2002, pp. 479–500.

    Chapter  Google Scholar 

  16. Thomas PT. Nonclinical evaluation of therapeutic cytokines: immunotoxicologic Issues. Toxicology 2002; 174:27–35.

    Article  CAS  PubMed  Google Scholar 

  17. Vilcek J. The cytokines: an overview. In: Thompson A, ed. The Cytokine Handbook. 3rd ed. San Diego Academic Press; 1998, pp. 1–20.

    Google Scholar 

  18. Bazan J. A novel family of growth factor receptors: a common binding domain in the growth hormone prolactin, erythropoietin and IL-6 receptors and the p75 IL-2 receptor B-chain. Biochem Biophys Research Commun 1989;164:788–795.

    Article  CAS  Google Scholar 

  19. Ihle J. Cytokine receptor signaling. Nature 1995;377:591–594.

    Article  CAS  PubMed  Google Scholar 

  20. Hirano T, Akira S, Taga T, Hishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990; 11:443–449.

    Article  CAS  PubMed  Google Scholar 

  21. Van Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990;8:253–278.

    Article  Google Scholar 

  22. Kammuler M, Ryffel B. Extrapolation of experimental safety data to humans: the interleukin-6 case. Clin Immunol Immunopathol 1997;83:5–17.

    Article  Google Scholar 

  23. Ryffel B, Car B, Gunn H, Roman D, Hiestand P, Mihatsch M. Interleukin-6 exacerbates glomerulonephritis in (NZBxNZW) Fl mice. Am J Pathol 1994; 144:927–937.

    CAS  PubMed  Google Scholar 

  24. Carson W, Yu H, Dierksheide J, et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162: 4943–4951.

    CAS  PubMed  Google Scholar 

  25. Carson WE, Dierksheide JE, Jabbour S, et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 2000;96:1465–1473.

    CAS  PubMed  Google Scholar 

  26. Talmadge J. Pharmacodynamic aspects of peptide administration of biological response modifiers. Adv Drug Delivery Rev 1998;33:241–252.

    Article  CAS  Google Scholar 

  27. Ammaan A, Beck S, DeGutzman L, et al. Transforming growth factor beta. Effect on soft tissue repair. Ann NY Acad Sci 1990;593:124–134.

    Article  Google Scholar 

  28. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720–1740.

    Article  CAS  PubMed  Google Scholar 

  29. Herzyk D. The immunogenicity of therapeutic cytokines. Curr Opinion Mol Ther 2003;5:167–171.

    CAS  Google Scholar 

  30. Yeung V, Chang J, Miller J, Barnett C, Stickler M, Harding F. Elimination of an immunodominant CD4+ T-cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. J Immunol 2004; 172: 6658–6665.

    CAS  PubMed  Google Scholar 

  31. Vial T, Descotes J. Immune-mediated side effects of cytokines in humans. Toxicology 1995; 105:31–57.

    Article  CAS  PubMed  Google Scholar 

  32. House R. Theory and practice of cytokine assessment in immunotoxicology. Methods 1999; 19:17–27.

    Article  CAS  PubMed  Google Scholar 

  33. Griffiths SA, Lumley CE. Non-clinical safety studies for biotechnologicallyderived Pharmaceuticals: Conclusions from an international workshop. Hum Exp Toxicol 1998; 17:63–83.

    Article  CAS  PubMed  Google Scholar 

  34. International Conference on Harmonization. Guidance S6. Preclinical safety evaluation of biotechnology-derived Pharmaceuticals; July 1997.

    Google Scholar 

  35. U.S. Food and Drug Administration. CDER Guidance for Industry. Immunotoxicology Evaluation of Investigational New Drugs; October 2002.

    Google Scholar 

  36. EMEA Committee for Proprietary Medicinal Products. Note for Guidance on Repeat Dose Toxicity. Appendix B. Guidance on Immunotoxicity. CPMP/ SWP/1042/99. July 2000.

    Google Scholar 

  37. International Conference on Harmonization Steering Committee Meeting. ICH 2004 Press Release June 9–10, 2004.

    Google Scholar 

  38. Old L. Tumor necrosis factor (TNF). Science 1985;230:630–632.

    Article  CAS  PubMed  Google Scholar 

  39. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985;82:8667–8671.

    Article  CAS  PubMed  Google Scholar 

  40. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;266:7313–7316.

    CAS  PubMed  Google Scholar 

  41. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–2272.

    Article  CAS  PubMed  Google Scholar 

  42. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM, for the IL-R Asthma Study Group. Efficacy of soluble IL-receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963–970.

    Article  CAS  PubMed  Google Scholar 

  43. Zavorotinskaya T, Tomkinson A, Murphy JE. Treatment of experimental asthma by long-term gene therapy directed against IL-and IL-13. Mol Ther 2003;7:155–162.

    Article  CAS  PubMed  Google Scholar 

  44. Ito H. I1-6 and Crohn’s disease. Curr Drug Targets Inflamm Allergy 2003;2: 125–130.

    Article  CAS  PubMed  Google Scholar 

  45. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386–391.

    Article  CAS  PubMed  Google Scholar 

  46. Moore K, de Waal Malefyt R, Coffmann R, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001;19:683–765.

    Article  CAS  Google Scholar 

  47. Li M, He S. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10:620–625.

    CAS  PubMed  Google Scholar 

  48. Herzyk D, Soos J, Maier C, et al. Immunopharmacology of recombinant human interleukin-18 in nonhuman primates. Cytokine 2002;20:38–48.

    Article  CAS  PubMed  Google Scholar 

  49. Braddock M, Quinn A, Canvin J. Therapeutic potential of targeting IL-1 and IL-18 in inflammation. Expert Opin Biol Ther 2004;4:847–860.

    Article  CAS  PubMed  Google Scholar 

  50. Okamura H, Tsutsui H. Kashiwamura S, Yoshimoto T, Nakanish K. Interleukin-18: A novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281–312.

    Article  CAS  PubMed  Google Scholar 

  51. Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of administration of recombinant interleukin-18 (rIL-18) or rIL-12 are mediated by Fas-Fas ligand and perforin-induced tumor apoptosis. J Immunol 1999; 163: 583–589.

    CAS  PubMed  Google Scholar 

  52. Herzyk D, Bugelski P, Hart T, Wier P. Preclinical safety of recombinant human interleukin-18. Toxicol Pathol 2003;31:554–561.

    CAS  PubMed  Google Scholar 

  53. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5 in cynomolgus monkeys. J Allerg Clin Immunol 2001; 108:250–257.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program Management Services, Covance Laboratories, Inc., Madison, WI

    Peter T. Thomas & Melissa S. Beck-Westermeyer

Authors
  1. Peter T. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa S. Beck-Westermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. DyPort Vaccine Company, LLC, Frederick, MD

    Robert V. House

  2. Poison Center and Pharmacovigilance Unit, Lyon Cedex, France

    Jacques Descotes

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Thomas, P.T., Beck-Westermeyer, M.S. (2007). Preclinical Approaches for the Safety Assessment of Cytokines. In: House, R.V., Descotes, J. (eds) Cytokines in Human Health. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-350-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-350-9_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-467-8

  • Online ISBN: 978-1-59745-350-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation